Andy, I respectfully disagree with you and Peter. I believe that the market reaction was simply a continuation of the sell the news that has become the norm in biotech. With first year projections from Ariad at $50 mil, I think the surprise will be to the upside (and in a significant way!).
One can definitely argue that the $4 bil MC was bloated to begin with. However, a 20% haircut on early approval even with the black box label was overdone, IMO.
One thing is for sure, I am getting real tired of holding through approvals and getting the rug pulled out from me.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.